Global Acute Rhinitis Market Segmentation, By Type (Allergic and Non-Allergic), Treatment (Antihistamines, Intranasal Corticosteroids, Immunotherapies, Decongestants, and Others), Route of Administration (Oral, Nasal, and Others), End-Users (ENT Centers, Clinics, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
Acute Rhinitis Market Analysis
Acute rhinitis market continues to evolve with advancements such as nasal sprays, antihistamines, and decongestants dominating treatment. Latest methods focus on targeted therapies and personalized medicine, enhancing efficacy and reducing side effects. Technology adoption includes AI-driven diagnostics and telemedicine for remote consultations. Growth is driven by rising air pollution and allergies globally, driving demand for effective and convenient treatments.
Acute Rhinitis Market Size
The global acute rhinitis market size was valued at USD 995.76 million in 2023 and is projected to reach USD 1,558.57 million by 2031, with a CAGR of 5.76% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Allergic and Non-Allergic), Treatment (Antihistamines, Intranasal Corticosteroids, Immunotherapies, Decongestants, and Others), Route of Administration (Oral, Nasal, and Others), End-Users (ENT Centers, Clinics, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Sanofi (France), Cigna (U.S.), Janssen Global Services, LLC (U.S.), FAES Farma (Spain), Hisamitsu Pharmaceutical Co.,Inc. (Japan), GLENMARK PHARMACEUTICALS LTD. (U.S.) , Olainfarm (Latvia), Boehringer Ingelheim International GmbH (Germany), Adroit Pharmachem Pvt Ltd (India), Avik Pharmaceutical Ltd. (India), GSK plc (U.K.), Sun Pharmaceutical Industries Ltd (India), Dr. Reddy’s Laboratories Ltd. (India), Hetero Healthcare Limited (India), Wellona Pharma (India), and Covis Pharma (Luxembourg)
|
|
Market Opportunities
|
|
Acute Rhinitis Market Definition
Acute rhinitis, commonly known as a cold or the common cold, is a viral infection of the upper respiratory tract. It causes inflammation of the nasal mucous membranes, leading to symptoms such as nasal congestion, runny nose, sneezing, and sore throat. It typically lasts for a few days to a week and is usually self-limiting, though it can be contagious.
Acute Rhinitis Market Dynamics
Drivers
- Increasing Prevalence of Allergic Rhinitis
The increasing prevalence of allergic rhinitis globally is significantly driving demand for treatments and management strategies, thereby expanding the market. For instance, in regions with high levels of air pollution and changing climate patterns, such as urban centers in developing countries, there has been a noticeable rise in allergic rhinitis cases. This trend underscores the urgent need for effective medications and preventive measures, propelling growth in the acute rhinitis market.
- Consumer Preferences for Non-Invasive Treatments
Consumer preferences for non-invasive treatments, such as nasal sprays and saline rinses, are driving innovation in the acute rhinitis market. These remedies offer effective relief without the side effects of traditional medications, appealing to a broader demographic seeking natural solutions. For instance, the increasing popularity of herbal remedies and essential oils showcases a shift towards holistic approaches, stimulating market diversification and the development of new, natural-based products.
Opportunities
- Advancements in Treatment Options
Advancements in pharmaceuticals and therapies for acute rhinitis present significant market opportunities by enhancing treatment effectiveness and targeting specific patient needs. For instance, the development of intranasal corticosteroids such as fluticasone propionate has revolutionized symptom management by reducing inflammation directly at the nasal mucosa, offering superior relief compared to older medications. Such innovations not only improve patient outcomes but also drive market expansion through increased adoption and demand for advanced treatment options.
- Government Initiatives for Acute Rhinitis
Government initiatives such as subsidies and healthcare policies aimed at managing chronic conditions such as rhinitis create significant market opportunities. For instance, funding for research into innovative treatments and public health campaigns promoting early diagnosis can spur demand for related pharmaceuticals and medical devices. These supportive measures not only improve patient outcomes but also stimulate growth in the acute rhinitis market by fostering a favorable regulatory environment and increasing accessibility to treatments.
Restraints/Challenges
- Healthcare Cost Containment
Healthcare cost-containment measures, such as stringent formulary restrictions and reimbursement policies, significantly hinder market access and pricing flexibility for acute rhinitis treatments. Pharmaceutical companies face increased barriers in securing favorable market positioning, limiting their ability to adjust prices or expand market reach. These constraints restrict profitability and innovation in the acute rhinitis sector, complicating efforts to navigate competitive dynamics and regulatory pressures effectively.
- Emerging Alternative Therapies
The increasing consumer preference for alternative therapies such as herbal remedies or nasal irrigation poses a significant challenge to the acute rhinitis market. These alternatives divert market share from traditional pharmaceutical treatments, challenging established treatment paradigms and market dynamics. This shift undermines the dominance of pharmaceutical solutions and complicates efforts to maintain market stability and growth.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Acute Rhinitis Market Scope
The market is segmented on the basis of type, treatment, dosage, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Allergic
- Non-Allergic
Treatment
- Antihistamines
- Intranasal Corticosteroids
- Immunotherapies
- Decongestants
- Others
Route of Administration
- Oral
- Nasal
- Others
End-Users
- ENT Centers
- Clinics
- Hospitals
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Acute Rhinitis Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, treatment, dosage, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe is expected to show significant growth in the acute rhinitis market, driven by increased adoption of advanced treatments by patients and hospitals. Governmental efforts to bolster research activities further contribute to this trend, fostering a favorable environment for market expansion and innovation in the region.
North America is expected to dominate the acute rhinitis market, driven by rising respiratory disorder cases and advanced treatment options. The region's robust healthcare infrastructure and high adoption rates of medications contribute to its prominence in managing rhinitis effectively.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Acute Rhinitis Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Sanofi (France)
- Cigna (U.S.)
- Janssen Global Services, LLC (U.S.)
- FAES Farma (Spain)
- Hisamitsu Pharmaceutical Co.,Inc. (Japan)
- GLENMARK PHARMACEUTICALS LTD. (U.S.)
- Olainfarm (Latvia)
- Boehringer Ingelheim International GmbH (Germany)
- Adroit Pharmachem Pvt Ltd (India)
- Avik Pharmaceutical Ltd. (India)
- GSK plc (U.K.)
- Sun Pharmaceutical Industries Ltd (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Hetero Healthcare Limited (India)
- Wellona Pharma (India)
- Covis Pharma (Luxembourg)
Latest Development in Acute Rhinitis Market
- In November 2022, A clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity was terminated due to insufficient subject enrollment. Sponsored by Allergy Therapeutics, known for subcutaneous and sublingual immunotherapy, the trial aimed to explore new treatments but faced challenges in recruiting participants
- In November 2020, Dr. Reddy's Laboratories announced plans to acquire several brands from Glenmark Pharmaceuticals, including Momat Rino and Glenspray variants, pending final approvals and procedural steps across Russia, Kazakhstan, Uzbekistan, and Ukraine
- In May 2021, Glenmark Pharmaceuticals launched Ryaltris nasal spray in India, expanding treatment options for moderate to severe allergic rhinitis. This initiative aimed to enhance growth prospects in the allergic rhinitis sector, providing a new therapeutic option for patients in the region
- In April 2021, ALK received FDA approval for its short ragweed pollen allergen extract, designed for patients aged 5 to 65 with short ragweed pollen-induced allergic rhinitis. This milestone marked a significant advancement in expanding treatment options for seasonal allergies in the United States
SKU-